PYC Therapeutics Limited
PYCXF
$0.8462
$0.178626.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 16.48M | 15.53M | 14.48M | 14.26M | 14.15M |
| Total Revenue | 16.48M | 15.53M | 14.48M | 14.26M | 14.15M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 16.48M | 15.53M | 14.48M | 14.26M | 14.15M |
| SG&A Expenses | 3.19M | 3.08M | 2.96M | 2.83M | 2.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.54M | 44.92M | 39.98M | 34.21M | 28.62M |
| Operating Income | -33.06M | -29.39M | -25.50M | -19.95M | -14.47M |
| Income Before Tax | -32.14M | -28.68M | -25.01M | -19.62M | -14.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.14 | -28.68 | -25.01 | -19.62 | -14.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 340.90K | 298.00K | 252.60K | 133.90K | 14.40K |
| Net Income | -31.80M | -28.38M | -24.76M | -19.49M | -14.29M |
| EBIT | -33.06M | -29.39M | -25.50M | -19.95M | -14.47M |
| EBITDA | -32.60M | -28.92M | -25.02M | -19.54M | -14.13M |
| EPS Basic | -0.07 | -0.07 | -0.06 | -0.05 | -0.04 |
| Normalized Basic EPS | -0.05 | -0.04 | -0.04 | -0.03 | -0.02 |
| EPS Diluted | -0.07 | -0.07 | -0.06 | -0.05 | -0.04 |
| Normalized Diluted EPS | -0.05 | -0.04 | -0.04 | -0.03 | -0.02 |
| Average Basic Shares Outstanding | 1.75B | 1.66B | 1.57B | 1.49B | 1.40B |
| Average Diluted Shares Outstanding | 1.75B | 1.66B | 1.57B | 1.49B | 1.40B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |